SOURCE: DC Brands International, Inc.

August 31, 2007 16:00 ET

DC Brands Signs With Walgreens Atlanta

DENVER, CO--(Marketwire - August 31, 2007) - DC Brands International (PINKSHEETS: DCBI) is excited to announce the company has reached an agreement with Walgreens Atlanta North District to sell its beverage -- Turn Left Energy Drink. This division of Walgreens consists of more than 100 store locations in the greater Atlanta region, and sale of the product will begin in approximately two weeks.

"All parties are excited with the roll out, and we intend to work with Walgreens for in-store promotions and radio media," said DC Brands Vice President of Sales Richard Muscarella. "We've been working on this deal for quite some time and are thrilled about what this may mean for the bigger picture. With the thousands of locations Walgreens operates nationwide, we are determined to make this first phase a resounding success."

ABOUT DC BRANDS INTERNATIONAL

DC Brands International, a publicly traded company under the ticker symbol (PINKSHEETS: DCBI), specializes in and manufactures unique energy drink brands. Established in 1998, DC Brands went public in 2005, and the company's first product, Dickens Energy Cider, launched in 2002 after a lengthy process in developing its distinctive flavor and packaging. Following the success of Dickens Energy Cider, the company chose to expand its product line with a beverage that filled the substantial NASCAR niche. With more than 75 million loyal fans, the NASCAR demographic presented an attractive opportunity to become one of the few racecar-themed energy drinks in the marketplace. Following much due diligence, research and testing, Turn Left Energy Drink recently came to fruition. For more information on DC Brands International, visit their website at www.TurnLeftEnergy.com and DickensEnergyCider.com

Note: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation, and the other risk factors listed from time to time in reports filed by DC Brands International with the Securities and Exchange Commission, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operation and Our Stock Price." The forward-looking statements contained in this news release represent judgments of the management of DC Brands International as of the date of this release. DC Brands International and its managers and agents undertake no obligation to publicly update any forward-looking statements.

Contact Information